Terms: = Germ cell tumor AND BCL3, P20749, 602, ENSG00000069399, D19S37, BCL4 AND Treatment
42 results:
1. Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression in melanoma cells.
Saamarthy K; Ahlqvist K; Daams R; Balagunaseelan N; Rinaldo-Matthis A; Kazi JU; Sime W; Massoumi R
BMC Cancer; 2024 Jan; 24(1):103. PubMed ID: 38238702
[TBL] [Abstract] [Full Text] [Related]
2. County-level disparities in care for patients with glioblastoma.
Ramapriyan R; Ramesh T; Yu H; Richardson LG; Nahed BV; Carter BS; Barker FG; Curry WT; Choi BD
Neurosurg Focus; 2023 Nov; 55(5):E12. PubMed ID: 37913538
[TBL] [Abstract] [Full Text] [Related]
3. Association Between Oncology Clinical Pathway Utilization and Toxicity and Cost Outcomes in Patients With Metastatic Solid tumors.
Liu Y; Mullangi S; Debono D; Chen X; Pham T; Fisch MJ; Gordon AS; Hershman DL
JCO Oncol Pract; 2023 Sep; 19(9):731-740. PubMed ID: 37384847
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic Factors and treatment Impact on Overall Survival in Adult Craniopharyngioma.
Awad M; Butterfield JT; Dhawan S; Tyler MA; Venteicher AS
World Neurosurg; 2023 May; 173():e132-e139. PubMed ID: 36773809
[TBL] [Abstract] [Full Text] [Related]
5. Investigation of radiomics based intra-patient inter-tumor heterogeneity and the impact of tumor subsampling strategies.
Henry T; Sun R; Lerousseau M; Estienne T; Robert C; Besse B; Robert C; Paragios N; Deutsch E
Sci Rep; 2022 Oct; 12(1):17244. PubMed ID: 36241749
[TBL] [Abstract] [Full Text] [Related]
6. A Nomogram for Predicting Early Recurrence in Patients with High-Grade Gliomas.
Zhou Q; Ke X; Xue C; Li S; Huang X; Zhang B; Zhou J
World Neurosurg; 2022 Aug; 164():e619-e628. PubMed ID: 35589036
[TBL] [Abstract] [Full Text] [Related]
7. The immune regulation of bcl3 in glioblastoma with mutated IDH1.
Fan S; Wu N; Chang S; Chen L; Sun X
Aging (Albany NY); 2022 Apr; 14(9):3856-3873. PubMed ID: 35488886
[TBL] [Abstract] [Full Text] [Related]
8. [Value of tumor growth rate in evaluating the early therapeutic efficacy of neuroendocrine neoplasm].
Zhou YT; Xia YF; Li Y; Zhu YJ; Chi Y; Jiang L
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):1000-1006. PubMed ID: 35399019
[No Abstract] [Full Text] [Related]
9. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed cell Death 1 and Anti-Programmed cell Death Ligand 1 Therapy.
Tang K; Seo J; Tiu BC; Le TK; Pahalyants V; Raval NS; Ugwu-Dike PO; Zubiri L; Naranbhai V; Carrington M; Gusev A; Reynolds KL; LeBoeuf NR; Asgari MM; Kwatra SG; Semenov YR
JAMA Dermatol; 2022 Feb; 158(2):189-193. PubMed ID: 35019948
[TBL] [Abstract] [Full Text] [Related]
10. Eye-Preserving Therapies for Advanced Retinoblastoma: A Multicenter Cohort of 1678 Patients in China.
Zhou C; Wen X; Ding Y; Ding J; Jin M; Liu Z; Wang S; Han M; Yuan H; Xiao Y; Wu L; Wang J; Li Y; Yu J; Wen Y; Ye J; Liu R; Chen Z; Xue S; Lu W; Liao H; Cui J; Zhu D; Lu F; Tang S; Wu Y; Yangkyi T; Zhang G; Wubuli M; Guo H; Wang X; He Y; Sheng X; Wang Q; Luo Y; Fan J; Qi J; Yu Z; Tan J; Liang J; Sun X; Jin L; Yang X; Zhang J; Ji X; Zhao J; Jia R; Fan X
Ophthalmology; 2022 Feb; 129(2):209-219. PubMed ID: 34536465
[TBL] [Abstract] [Full Text] [Related]
11. Economic implications of the modern treatment paradigm of glioblastoma: an analysis of global cost estimates and their utility for cost assessment.
Goel NJ; Bird CE; Hicks WH; Abdullah KG
J Med Econ; 2021; 24(1):1018-1024. PubMed ID: 34353213
[TBL] [Abstract] [Full Text] [Related]
12. CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma.
Voce DJ; Bernal GM; Cahill KE; Wu L; Mansour N; Crawley CD; Campbell PS; Arina A; Weichselbaum RR; Yamini B
Sci Rep; 2021 Mar; 11(1):5665. PubMed ID: 33707466
[TBL] [Abstract] [Full Text] [Related]
13. Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases.
Ismail RK; Sikkes NO; Wouters MWJM; Hilarius DL; Pasmooij AMG; van den Eertwegh AJM; Aarts MJB; van den Berkmortel FWPJ; Boers-Sonderen MJ; de Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije BJ; van der Veldt AAM; Vreugdenhil A; van Dartel M; de Boer A
Melanoma Res; 2021 Feb; 31(1):58-66. PubMed ID: 33351553
[TBL] [Abstract] [Full Text] [Related]
14. Impact of tumor-Infiltrating Lymphocytes on Overall Survival in Merkel cell Carcinoma.
Butala AA; Jain V; Reddy VK; Sebro RA; Song Y; Karakousis G; Mitchell TC; Lukens JN; Shabason JE
Oncologist; 2021 Jan; 26(1):63-69. PubMed ID: 32886418
[TBL] [Abstract] [Full Text] [Related]
15. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
[TBL] [Abstract] [Full Text] [Related]
16. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.
Esse S; Mason KJ; Green AC; Warren RB
JAMA Dermatol; 2020 Jul; 156(7):787-794. PubMed ID: 32432649
[TBL] [Abstract] [Full Text] [Related]
17. [Comparison between minimally invasive surgery and traditional laminectomy in the resection of schwannoma of lumbar vertebra].
Jiang WJ; Wang YZ; Yang J; Jia WQ
Zhonghua Yi Xue Za Zhi; 2020 Feb; 100(4):274-278. PubMed ID: 32075355
[No Abstract] [Full Text] [Related]
18. A Hydroquinone-Based Derivative Elicits Apoptosis and Autophagy via Activating a ROS-Dependent Unfolded Protein Response in Human Glioblastoma.
Zappavigna S; Cossu AM; Abate M; Misso G; Lombardi A; Caraglia M; Filosa R
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31390836
[TBL] [Abstract] [Full Text] [Related]
19.
Wu L; Bernal GM; Cahill KE; Pytel P; Fitzpatrick CA; Mashek H; Weichselbaum RR; Yamini B
Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973405
[TBL] [Abstract] [Full Text] [Related]
20. Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?
Zanello M; Roux A; Ursu R; Peeters S; Bauchet L; Noel G; Guyotat J; Le Reste PJ; Faillot T; Litre F; Desse N; Emery E; Petit A; Peltier J; Voirin J; Caire F; Barat JL; Vignes JR; Menei P; Langlois O; Dezamis E; Carpentier A; Dam Hieu P; Metellus P; Pallud J;
J Neurooncol; 2017 Nov; 135(2):285-297. PubMed ID: 28726173
[TBL] [Abstract] [Full Text] [Related]
[Next]
